Vertex: CF Monopoly, Looking To Expand [Seeking Alpha]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Seeking Alpha
MarianVejcik/iStock via Getty ImagesIn October 2020, IconcludedVertex (NASDAQ:VRTXAfter all, the company has seen solid growth, it was very profitable, as it controlled the "CF" market, a situation which still is the case today.Former TakeLate in 2020, shares of Vertex sold-off overnight from $300 to $220 per share in response to disappointing research results, thereby wiping out the entire gains for the year so far at the time. Despite the decent risk-reward based on the operating performance at the time, I feared a value-trap scenario.Shares sold off after Vertex decided to stop the Phase 2 trials of VX-814 on the back of elevated liver enzyme levels being observed, leaving the company to conclude that it was best to halt the study, as new structure should start in the first half of 2021.Founded in 1989, Vertex has been struggling for a long time as its luck changed in 2012 when the FDA approved KALYDECO for the treatment of cystic fibrosis. This life-threatening disease impacts one
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Pioneer Institute study finds IRA discourages non-opioid drug innovation [Yahoo! Finance]Yahoo! Finance
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older [Yahoo! Finance]Yahoo! Finance
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and OlderBusiness Wire
- The Americas’ Fastest Growing Companies [FT.com - Mergermarket]FT.com - Mergermarket
- The Americas’ Fastest Growing Companies [Financial Times (FT.com) (UK)]Financial Times
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/17/24 - Form 4
- 4/16/24 - Form PX14A6G
- 4/11/24 - Form SC
- VRTX's page on the SEC website